The Top 5 Biosimilar Articles for the Week of January 18

January 22, 2021

Here are the top 5 biosimilar articles for the week of January 18, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of January 18, 2021.

Number 5: Results were inconclusive in a study of hypertension and proteinuria in 75 patients treated with bevacizumab reference vs biosimilar products, investigators reported at the ASCO Gastrointestinal Cancers Symposium 2021.

Number 4: Switching patients with inflammatory bowel disease (IBD) from the CT-P13 infliximab biosimilar to the SB2 infliximab biosimilar appears to be safe and effective whether 1 or more switches between biosimilars and the originator product were involved, investigators concluded in a retrospective study.

Number 3: Investigators have demonstrated that initial uptake of the first bevacizumab biosimilar (Mvasi, Amgen) in the United States was strongest for patients receiving treatment for metastatic colorectal cancer (mCRC).

Number 2: Sonia T. Oskouei, PharmD, BCMAS, DPLA, wrote an opinion piece on why ophthalmology biosimilars are a therapeutic area to watch in 2021.

Number 1: The Center for Biosimilars® reported on developments at the International Generic and Biosimilar Medicines Association (IGBA), Celltrion, Innovent Biologics, and Kamada.

To read all of these articles and more, visit centerforbiosimilars.com.